A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid Tumors

Sponsor
Beidahuang Industry Group General Hospital
Study ID
NCT06537505
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Adebrelimab — DRUG
    Q3W,IV
  • Apatinib — DRUG
    QoD
  • microwave ablation — PROCEDURE
    microwave ablation

Study Details

This is a multi-center, phase Il trial to evaluate the efficacy and safety of microwave ablation combined with immunotherapy ± anti-angiogenic drugs in the treatment of advanced second-line and above solid tumors.

Key Dates

Start date
Aug 5, 2024
Status verified
Aug 2024
Primary completion
Apr 1, 2027
Completion
Aug 31, 2027

Study Design

Enrollment
60 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: microwave ablation combined with immunotherapy and anti-angiogenic drugs
    microwave ablation combined with adebrelimab and apatinib
  • Experimental: microwave ablation combined with immunotherapy
    microwave ablation combined with adebrelimab

Primary Outcome Measure

Objective Response Rate [ Time Frame: up to 24 months ]

Central Contacts

Related Studies